Skip to main content
. Author manuscript; available in PMC: 2015 Apr 2.
Published in final edited form as: Mol Genet Metab. 2014 Feb 21;112(1):17–24. doi: 10.1016/j.ymgme.2014.02.007

Table 3.

Hyperammonemic Crises During GPB Treatment as Compared with Pre-Enrollment

12-month pre-enrollment (NaPBA)
(N=49)
12 months on study (GPB)
(N=49)

Patients with HA Crises: n (%) 21 (42.9) 12 (24.5)
  Age 29 days- <2 years (N=7) 5 (71.4) 2 (28.6)
  Age 2–5 years (N=16) 10 (62.5) 5 (31.3)
  Age 6–11 years (N=17) 2 (11.8) 4 (23.5)
  Age 12–17 years (N=9) 4 (44.4) 1 (11.1)

Total number of HA Crises 38 17
  Age 29 days- <2 years (N=7) 6 2
  Age 2–5 years (N=16) 23 10
  Age 6–11 years (N=17) 3 4
  Age 12–17 years (N=9) 6 1

Number of HA Crises per Patient: mean (SD) 0.78 (1.279) 0.35 (0.830)
  Age 29 days- <2 years (N=7) 0.86 (0.690) 0.29 (0.488)
  Age 2–5 years (N=16) 1.44 (1.825) 0.63 (1.310)
  Age 6–11 years (N=17) 0.18 (0.529) 0.24 (0.437)
  Age 12–17 years (N=9) 0.67 (1.000) 0.11 (0.333)

Precipitating Factors (% of all HACs)
  Infection 6 (15.8) 2 (11.8)
  Intercurrent illness 10 (26.3) 6 (35.3)
  Non-compliance with medication 4 (10.5) 0
  Non-compliance with diet 4 (10.5) 0
  Other 14 (36.8) 3 (17.6)
  None 7 (18.4) 7 (41.2)

Clinical Symptoms: n (% of all HACs)
  Abnormal neurology 0 2 (11.8)
  Brain edema 0 1 (5.9)
  Chronic migraine headaches 2 (5.3) 0
  Episodic lethargy 14 (36.8) 5 (29.4)
  Protein intolerance 2 (5.3) 4 (23.5)
  Psychosis (episodic) 1 (2.6) 0
  Recurrent vomiting 24 (63.2) 13 (76.5)
  Other 18 (47.4) 4 (23.5)
  None 1 (2.6) 1 (5.9)